Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

Apellis Announces FDA Fast Track Designation for APL-2 in PNH

C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience hemolysis and require RBC transfusions despite receiving treatment with eculizumab Louisville, Ky., December 20, 2016 –  Apellis Pharmaceuticals, Inc., a…

Clyde Launches New Contractility Service – CellOPTIQ®-X

Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma clients. CellOPTIQ®-X represents a revolution in contractility assays, offering: Early detection of contractility toxicities Higher throughput, cost-effective solution Reduction in…